← All reports Share via email

Healthcare report · Week 42 · Oct 12 – 16, 2026

Health care: who led, who lagged, what comes next

Why health care led the market in the week to Oct 16, the companies the trend screens flagged, the year's outliers and the reports ahead — closing prices, Fri Oct 9 to Fri Oct 16, 2026.

$176.71Health care sector fund (XLV)+3.5%
$763.25S&P 500 (SPY)-2.0%
$183.47Technology sector fund (XLK)-7.7%
$201.99Biotech fund (IBB)-2.2%
47 of 54Health-care stocks up · typical move+4.0%
+639%Moderna, year to date (best)

Summary

Why health care led this week

Over the week to Oct 16, investors moved money out of technology and into defensive sectors, and health care was the third-best of the 11 sectors.

Return over the week (%), the 11 S&P 500 sector funds, Oct 9 to Oct 16
  1. Consumer Staples (XLP)+5.0%
  2. Energy (XLE)+4.9%
  3. Health Care (XLV)+3.5%
  4. Materials (XLB)+3.0%
  5. Utilities (XLU)+1.9%
  6. Financials (XLF)+1.4%
  7. Real Estate (XLRE)+1.3%
  8. Communication Svcs (XLC)-0.1%
  9. Consumer Disc. (XLY)-0.3%
  10. Industrials (XLI)-0.9%
  11. Technology (XLK)-7.7%

Health care was the third-best of the 11 S&P 500 sectors in the week to Fri Oct 16: the sector fund XLV gained 3.5%, behind consumer staples (+5.0%) and energy (+4.9%). The S&P 500 fund (SPY) lost 2.0% and technology (XLK) lost 7.7%. Over the past month health care ranks second of the 11 (+5.3%).

Health-care companies sell medicines, devices and care that people need in good times and bad, so their profits depend less on the economy than a chip maker's. That is why investors reach for them when they sell growth stocks. XLV closed the week at $176.71, its highest close of the past year.

On Friday alone (1 day), the typical defensive blue-chip stock moved +0.80% while the typical large growth stock moved −4.64% — a gap of 5.44 percentage points in favour of the defensive stocks.

Interest rates eased a little. The 10-year Treasury yield stood at 5.10% at its latest reading (Oct 15), down 0.12 points from a week earlier, and long-dated Treasury bonds (TLT) gained 2.7% over the week. Lower yields help defensive sectors, whose steady profits are valued much like bond income.

What would change this

If the broad market wins back this week's loss — the S&P 500 fund (SPY) closing above last Friday's $778.57 — investors would have less reason to hide in defensive stocks, and health care's lead would likely narrow.

The scoreboard

Of the 54 large health-care companies tracked here, 47 rose over the week to Oct 16; the typical one gained 4.0%.

Return over the week (%), the 15 best and 5 weakest of 54 large health-care companies, Oct 9 to Oct 16
  1. IDEXX Laboratories (IDXX)+8.2%
  2. CVS Health (CVS)+7.2%
  3. Medtronic (MDT)+7.1%
  4. McKesson (MCK)+7.0%
  5. Cigna (CI)+7.0%
  6. Cardinal Health (CAH)+6.9%
  7. Eli Lilly (LLY)+6.6%
  8. GSK (GSK)+6.5%
  9. Zimmer Biomet (ZBH)+6.5%
  10. Stryker (SYK)+6.2%
  11. Zoetis (ZTS)+6.1%
  12. Regeneron (REGN)+5.9%
  13. Centene (CNC)+5.8%
  14. UnitedHealth (UNH)+5.8%
  15. GE HealthCare (GEHC)+5.8%
  16. Vertex (VRTX)-2.0%
  17. Johnson & Johnson (JNJ)-2.2%
  18. Moderna (MRNA)-3.1%
  19. Humana (HUM)-4.3%
  20. Insmed (INSM)-4.3%

47 of the 54 companies rose over the week and 7 fell; the typical one gained 4.0%. The biggest gains: IDEXX Laboratories (+8.2%), CVS Health (+7.2%) and Medtronic (+7.1%). The weakest: Humana (−4.3%), Insmed (−4.3%) and Moderna (−3.1%). By group, insurers did best (typical company +5.5%) and biotech companies least (+1.4%).

Return of the typical (median) company in each health-care group (%), to Oct 16
Group1 week1 month3 monthsYear to date
Insurers 6 companies+5.5%+5.2%+4.4%+21.9%
Hospitals, pharmacies & distributors 7 companies+5.3%+7.0%+20.9%+16.4%
Tools, labs & diagnostics 7 companies+4.2%+7.8%+13.9%+0.1%
Medical devices 12 companies+4.1%+2.0%+4.5%-8.7%
Drugmakers 12 companies+3.6%-0.6%+1.7%+10.0%
Biotech 10 companies+1.4%+1.8%+16.8%+15.9%
Health-care industry funds against the market, return (%) to Oct 16
Fund1 week1 month3 monthsYear to date
XLV Health care sector fund+3.5%+4.7%+11.0%+14.2%
IBB Biotech fund (largest companies weigh most)-2.2%-2.5%+8.3%+19.7%
XBI Biotech fund (equal weight)-6.2%-8.8%-4.4%+18.4%
IHI Medical-device fund+3.9%+4.0%+6.2%-13.5%
IHF Health-care providers fund+3.3%+3.7%+3.9%+22.3%
SPY S&P 500 fund-2.0%+0.1%+2.9%+11.9%
XLK Technology sector fund-7.7%-2.4%+4.4%+27.4%

Among biotech, size mattered: the fund where the largest companies weigh most (IBB) lost 2.2%, while the equal-weight fund (XBI), where small drug developers count as much as the giants, lost 6.2%. Medical-device makers (IHI) gained 3.9% and health-care providers (IHF) gained 3.3%.

Return (%) of 54 large health-care companies over four periods, to the Oct 16 close
Ticker1 week1 month3 monthsYear to date
LLY Eli Lilly · Drugmakers+6.6%+9.1%+9.6%+17.0%
GSK GSK · Drugmakers+6.5%-3.0%-1.1%+1.0%
ZTS Zoetis · Drugmakers+6.1%+8.7%+4.2%-36.9%
NVS Novartis · Drugmakers+4.8%+6.9%+0.7%+9.2%
PFE Pfizer · Drugmakers+4.6%+7.0%+19.5%+18.8%
AZN AstraZeneca · Drugmakers+3.9%-0.4%+0.5%-10.0%
ABBV AbbVie · Drugmakers+3.2%+8.1%+12.7%+24.9%
SNY Sanofi · Drugmakers+1.4%-5.9%-7.7%-16.2%
BMY Bristol Myers Squibb · Drugmakers+1.1%-4.9%-0.7%+10.8%
NVO Novo Nordisk · Drugmakers+0.5%-10.1%-21.7%-23.7%
MRK Merck · Drugmakers+0.2%-0.8%+17.3%+38.7%
JNJ Johnson & Johnson · Drugmakers-2.2%-5.4%+2.7%+23.5%
REGN Regeneron · Biotech+5.9%+0.2%+17.6%+2.4%
AMGN Amgen · Biotech+4.2%+13.9%+18.8%+32.1%
ONC BeOne Medicines · Biotech+4.1%+4.4%+18.8%+21.5%
GILD Gilead Sciences · Biotech+3.3%+3.5%+17.2%+27.2%
BIIB Biogen · Biotech+3.1%+6.2%+16.4%+32.2%
ALNY Alnylam · Biotech-0.4%-5.6%-15.0%-41.7%
ARGX argenx · Biotech-0.7%-17.7%-3.2%-2.6%
VRTX Vertex · Biotech-2.0%-3.2%+4.0%+10.2%
MRNA Moderna · Biotech-3.1%+37.9%+266.5%+639.3%
INSM Insmed · Biotech-4.3%-22.4%-10.0%-44.7%
MDT Medtronic · Medical devices+7.1%+2.1%+13.8%-1.4%
ZBH Zimmer Biomet · Medical devices+6.5%+0.8%+5.9%+5.6%
SYK Stryker · Medical devices+6.2%+5.2%-7.7%-16.2%
ABT Abbott · Medical devices+5.3%+2.6%+3.2%-16.3%
BDX Becton Dickinson · Medical devices+4.3%+5.7%+24.1%+25.7%
PODD Insulet · Medical devices+4.3%-0.3%-15.7%-50.4%
BSX Boston Scientific · Medical devices+3.9%+1.9%+1.4%-53.5%
RMD ResMed · Medical devices+3.9%+4.6%+20.3%-0.8%
ALC Alcon · Medical devices+3.2%+1.5%-5.5%-16.0%
DXCM Dexcom · Medical devices+2.3%-2.1%+13.7%+29.6%
EW Edwards Lifesciences · Medical devices+1.6%-1.9%+1.9%+1.6%
ISRG Intuitive Surgical · Medical devices+0.7%+11.2%+20.8%-24.7%
IDXX IDEXX Laboratories · Tools, labs & diagnostics+8.2%+10.6%-0.6%-17.2%
GEHC GE HealthCare · Tools, labs & diagnostics+5.8%+8.0%+10.7%-15.2%
TMO Thermo Fisher · Tools, labs & diagnostics+4.9%+4.8%+31.1%+19.1%
DHR Danaher · Tools, labs & diagnostics+4.2%+7.8%+13.9%+0.1%
STE Steris · Tools, labs & diagnostics+3.9%+7.0%+3.8%-12.2%
IQV IQVIA · Tools, labs & diagnostics+2.7%-0.9%+30.9%+18.4%
A Agilent · Tools, labs & diagnostics+1.4%+10.6%+32.8%+27.1%
CI Cigna · Insurers+7.0%+9.5%+6.5%+9.8%
UNH UnitedHealth · Insurers+5.8%+7.0%-4.8%+21.6%
CNC Centene · Insurers+5.8%+3.1%+5.0%+68.1%
MOH Molina Healthcare · Insurers+5.3%+1.1%-9.7%+19.5%
ELV Elevance Health · Insurers+3.8%+3.4%+12.0%+22.2%
HUM Humana · Insurers-4.3%+7.5%+3.8%+61.3%
CVS CVS Health · Hospitals, pharmacies & distributors+7.2%+2.3%-14.2%+16.4%
MCK McKesson · Hospitals, pharmacies & distributors+7.0%+14.2%+20.9%+22.5%
CAH Cardinal Health · Hospitals, pharmacies & distributors+6.9%+12.2%+12.5%+23.6%
COR Cencora · Hospitals, pharmacies & distributors+5.3%+10.2%+12.2%+0.9%
UHS Universal Health Services · Hospitals, pharmacies & distributors+4.4%+2.4%+22.9%-15.1%
HCA HCA Healthcare · Hospitals, pharmacies & distributors+1.7%+7.0%+23.9%-1.7%
THC Tenet Healthcare · Hospitals, pharmacies & distributors+1.3%+2.0%+37.5%+34.5%

The 54 companies: US-listed health-care companies worth roughly $10B or more, grouped by what they sell — European and other foreign drugmakers through their US-listed shares (ADRs, US-traded certificates for a foreign company's stock). The tobacco companies Altria and British American Tobacco, which the market's trend screens file under health care, are covered in the Consumer staples report instead; CVS Health, which the screens file under consumer staples, is here (pharmacies plus the insurer Aetna). Returns are from daily closing prices, not counting dividends.

What would change this

Breadth is what made this week a rotation: 47 of 54 rose. If the gains narrow to a handful of large drugmakers and insurers while most of the group falls, money would be thinning out of the sector rather than spreading through it.

What the trending screens flagged

The trend screens point up on 11 health-care companies worth $10B or more this week and down on 2.

The market's trend screens look for stocks crossing their average-price lines, reaching momentum extremes or making unusually large moves. They check 656 US-listed companies worth $10B or more. In the five sessions to Oct 15, their signals point up on 11 health-care companies — Eli Lilly, AbbVie, UnitedHealth, Novartis, Abbott, Medtronic, McKesson, Stryker, IDEXX Laboratories, BeOne Medicines and Royalty Pharma — and down on 2: Bristol Myers Squibb and HCA Healthcare.

Health-care companies worth $10B or more that the trend screens flagged in the five sessions to Oct 15
TickerCompanySignals point1 weekWhat the screens saw
IDXXIDEXX LaboratoriesUp+8.2%closed back above its 150-day average; short-term trend turned up (9-day average crossed above the 20-day); closed back above its 50-day average; closed back above its 9-day average; RSI 66, near the overbought line; moved +8.2% in a week
LLYEli LillyUp+6.6%closed back above its 50-day average; RSI 69, near the overbought line; an unusually large one-day gain for its size (+3.5%); moved +6.6% in a week
ONCBeOne MedicinesUp+4.1%short-term trend turned up (9-day average crossed above the 20-day); closed back above its 50-day average; closed back above its 9-day average; traded more than twice its usual daily volume
NVSNovartisUp+4.8%short-term trend turned up (9-day average crossed above the 20-day); closed back above its 50-day average; closed right at its 150-day average
RPRXRoyalty Pharma plcUp+7.1%short-term trend turned up (9-day average crossed above the 20-day); closed back above its 50-day average; a 'shooting star' day: rallied, then gave the gain back to close near the low; closed back above its 9-day average; moved +7.1% in a week
SYKStrykerUp+6.2%short-term trend turned up (9-day average crossed above the 20-day); closed back above its 9-day average; moved +6.2% in a week
MDTMedtronicUp+7.1%short-term trend turned up (9-day average crossed above the 20-day); closed back above its 50-day average; moved +7.1% in a week
MCKMcKessonUp+7.0%RSI rose above 70 (overbought); moved +7.0% in a week
UNHUnitedHealthUp+5.8%short-term trend turned up (9-day average crossed above the 20-day); closed back above its 50-day average
ABTAbbottUp+5.3%short-term trend turned up (9-day average crossed above the 20-day); closed back above its 9-day average
ABBVAbbVieUp+3.2%RSI rose above 70 (overbought); RSI turned down from overbought
BMYBristol Myers SquibbDown+1.1%closed below its 150-day average; closed back above its 9-day average; a 'shooting star' day: rallied, then gave the gain back to close near the low; RSI turned up from oversold; RSI fell below 30 (oversold)
HCAHCA HealthcareDown+1.7%RSI turned down from overbought; RSI rose above 70 (overbought)

Across all health-care companies worth $2B or more, 98 flashed at least one upward signal in those five sessions and 82 a downward one.

The screens also list British American Tobacco and Altria under health care; they are tobacco companies and appear in the Consumer staples report.

50-day / 150-day average
The average closing price of the past 50 or 150 sessions — common gauges of the medium-term trend. Closing back above one is read as the trend turning up.
9-day and 20-day averages
Short-term trend lines that weight recent days most; the 9-day crossing above the 20-day marks a short-term turn up.
RSI
The relative strength index (0–100) compares recent gains with recent losses; above 70 is usually read as overbought, below 30 as oversold.
Candle patterns
Shapes of a single day's trading range — e.g. a 'shooting star' rallies and then gives the gain back by the close.
What would change this

Bristol Myers Squibb is the one large health-care name the screens point down on. It closed below its 150-day average ($60.16, 0.7% over Friday's close). A close back above that line would end the slide in its medium-term trend.

The year's outliers

Year to date, health care holds one of the market's biggest winners — Moderna, +639% — and some of its sharpest losers.

Year-to-date return (%), the 8 best and 8 weakest of 54 large health-care companies, Dec 31 to Oct 16
  1. Moderna (MRNA)+639.3%
  2. Centene (CNC)+68.1%
  3. Humana (HUM)+61.3%
  4. Merck (MRK)+38.7%
  5. Tenet Healthcare (THC)+34.5%
  6. Biogen (BIIB)+32.2%
  7. Amgen (AMGN)+32.1%
  8. Dexcom (DXCM)+29.6%
  9. IDEXX Laboratories (IDXX)-17.2%
  10. Novo Nordisk (NVO)-23.7%
  11. Intuitive Surgical (ISRG)-24.7%
  12. Zoetis (ZTS)-36.9%
  13. Alnylam (ALNY)-41.7%
  14. Insmed (INSM)-44.7%
  15. Insulet (PODD)-50.4%
  16. Boston Scientific (BSX)-53.5%

Moderna (MRNA) is the year's best performer here by far: +639% since Dec 31, so the shares are worth about 7.4 times what they were at the start of the year. Biotech built on mRNA, the technology behind its COVID-19 vaccine; it is developing cancer vaccines with Merck. The run gathered pace in August, when Moderna and Merck reported that their personalised cancer vaccine cut the return of melanoma in a late-stage trial, and again this month on news of a government push to speed up cancer vaccines and the stock's entry into the Nasdaq-100 (Moderna stock surges more than 600% in 2026 (Quartz); Moderna shares skyrocket on success of cancer drug trial (Forbes, Aug 19)). This week it lost 3.1%, including a 7.8% drop on Friday; it closed 40.7% above its 50-day average with an RSI of 62, and reports next on Nov 6.

The insurers are the year's other winners: the typical one is up 21.9% since Dec 31, led by Centene (+68.1%) and Humana (+61.3%). In April the US government set next year's payments to private Medicare plans far above its first proposal, which lifted the group (Schaeffer’s, Apr 7). This week the typical insurer gained 5.5%.

The laggards. At the other end, Boston Scientific (−53%), Insulet (−50%), Insmed (−45%), Alnylam (−42%) and Zoetis (−37%) are the weakest this year. Boston Scientific — Medical devices for the heart and blood vessels, including heart-rhythm treatment systems. Insulet — Tubeless insulin pumps (Omnipod). Insmed — Biotech: treatments for rare lung diseases. Even so, 8 of the 10 weakest rose this week — the rotation lifted most of the sector.

What would change this

Moderna closed 40.7% above its 50-day average ($154.93). A close below that line would mean the year's biggest run in health care has broken its short-term trend.

Earnings: this week and ahead

UnitedHealth and Johnson & Johnson reported this week; the sector's next reports start on Oct 20, with 7 reports in the coming week.

UnitedHealth reported its July–September 2026 results on Oct 13 before the market opened: earnings per share (adjusted) of $4.69 beat the $4.12 analysts expected by 13.8%. The shares moved −0.2% that day and +5.8% over the week (company release).

Johnson & Johnson also reported this week and raised its full-year outlook, but a one-time charge for its proposed talc litigation settlement cut its reported profit (company release). Its results are not in the earnings data used here; its shares lost 2.2% on the week.

Health-care companies in this report with results due Oct 19 – Oct 23

Mon Oct 190

Before market open

—

After market close

—

Tue Oct 201

Before market open

—

After market close

ISRG$151B±8.5%

Wed Oct 215

Before market open

DHR$163B±6.0%
TMO$258B±5.2%
ABT$181B±4.8%
ELV$92.9B

After market close

MOH$11.1B

Thu Oct 221

Before market open

ARGX$52.5B

After market close

—

Fri Oct 230

Before market open

—

After market close

—

Companies reporting earnings, by day and time: US-listed, market value $10.0B or more — 7 reports in all. ±% is the share-price move options traders expect around the report, where options data is available; the bar compares it with the week's largest. Option-implied moves exist only for companies worth $100B or more.

The share-price move options traders expect around each report, against the average move after its past reports: Intuitive Surgical ±8.5% vs ±6.7% (larger than, 8 reports); Thermo Fisher ±5.2% vs ±5.1% (about in line with, 8 reports); Abbott ±4.8% vs ±5.9% (smaller than, 7 reports); Danaher ±6.0% vs ±5.1% (larger than, 8 reports).

Reporting later, Oct 26 – Nov 6: 41 health-care companies in this report
DateTickerCompanyMarket valueTimeMove options expectAvg move, past reports (n)
Tue Oct 27NVSNovartis$287BBefore open±3.3%±2.6% (4)
Tue Oct 27HCAHCA Healthcare$101BBefore open±5.6%±4.7% (8)
Tue Oct 27IQVIQVIA$44.6BBefore openn/an/a
Tue Oct 27CNCCentene$34.8BBefore openn/an/a
Tue Oct 27UHSUniversal Health Services$11.0BAfter closen/an/a
Wed Oct 28GSKGSK$99.2BBefore openn/an/a
Wed Oct 28BSXBoston Scientific$64.0BBefore openn/an/a
Wed Oct 28BIIBBiogen$34.8BBefore openn/an/a
Wed Oct 28GEHCGE HealthCare$31.8BBefore openn/an/a
Thu Oct 29LLYEli Lilly$1.18TBefore open±5.7%±8.0% (8)
Thu Oct 29MRKMerck$358BBefore open±5.8%±2.4% (8)
Thu Oct 29BMYBristol Myers Squibb$124BBefore open±3.9%±4.3% (8)
Thu Oct 29ALNYAlnylam$31.3BBefore openn/an/a
Thu Oct 29THCTenet Healthcare$22.2BBefore openn/an/a
Thu Oct 29INSMInsmed$21.7BBefore openn/an/a
Thu Oct 29GILDGilead Sciences$195BAfter closen/a±4.6% (8)
Thu Oct 29SYKStryker$112BAfter close±6.1%±3.5% (8)
Thu Oct 29RMDResMed$34.1BAfter closen/an/a
Thu Oct 29DXCMDexcom$33.1BAfter closen/an/a
Fri Oct 30ABBVAbbVie$501BBefore open±3.7%±3.5% (8)
Fri Oct 30SNYSanofi$98.3BBefore openn/an/a
Fri Oct 30REGNRegeneron$82.0BBefore openn/an/a
Fri Oct 30AZNAstraZeneca$258BAfter close±3.5%±2.4% (4)
Mon Nov 2IDXXIDEXX Laboratories$43.1BBefore openn/an/a
Mon Nov 2VRTXVertex$129BAfter closen/a±6.2% (8)
Tue Nov 3PFEPfizer$168BBefore open±4.0%±2.2% (8)
Tue Nov 3AMGNAmgen$235BAfter close±4.0%±4.9% (8)
Wed Nov 4NVONovo Nordisk$174BBefore open±6.1%±3.6% (4)
Wed Nov 4CVSCVS Health$118BBefore open±5.7%±5.7% (8)
Wed Nov 4CORCencora$65.2BBefore openn/an/a
Wed Nov 4ZBHZimmer Biomet$18.0BBefore openn/an/a
Wed Nov 4MCKMcKesson$116BAfter close±5.4%±4.2% (8)
Wed Nov 4EWEdwards Lifesciences$50.8BAfter closen/an/a
Wed Nov 4STESteris$21.9BAfter closen/an/a
Thu Nov 5CICigna$79.0BBefore openn/an/a
Thu Nov 5CAHCardinal Health$58.7BBefore openn/an/a
Thu Nov 5BDXBecton Dickinson$52.8BBefore openn/an/a
Thu Nov 5ONCBeOne Medicines$42.5BBefore openn/an/a
Thu Nov 5ZTSZoetis$32.4BBefore openn/an/a
Fri Nov 6MRNAModerna$94.4BBefore openn/an/a
Fri Nov 6HUMHumana$51.9BBefore openn/an/a

Move options expect: the share-price move options traders price in around the report (companies worth $100B or more only). Average move: the average size of the share-price move the day after its reports over the past two years. “No extra move priced”: options price no more movement around the report than on an ordinary day — itself a finding.

What would change this

If either of the first large reports of the coming week closes outside the range options price, measured from Friday's close, between Oct 21 and Oct 22 — Intuitive Surgical (reports Oct 20 after the close; ±8.5% → below $390.35 or above $463.05); Thermo Fisher (reports Oct 21 before the open; ±5.2% → below $654.33 or above $725.67) — results, not the rotation, would be setting the sector's direction.

How stretched the move is

After the week's gains, 37 of 54 large health-care companies trade above their 50-day average and 5 show overbought readings.

The RSI (relative strength index, 0–100) compares recent gains with recent losses; above 70 is usually read as overbought — a sign a run has gone far quickly — and below 30 as oversold. 5 of the 54 companies closed the week at 70 or above: McKesson (76), Cardinal Health (74), Cigna (73), AbbVie (71) and Cencora (70). 1 sits at 30 or below (Insmed). The sector fund XLV's RSI is 66.

37 of the 54 close above their 50-day average and 37 of 54 above their 200-day — the average closing price of the past 200 sessions, a common gauge of the long-term trend. XLV sits 4.0% above its 50-day and 12.2% above its 200-day. 3 companies closed within 1% of their highest close of the past year: Thermo Fisher, Gilead Sciences and Elevance Health.

The 10 health-care companies furthest above their 50-day average, Oct 16 close
TickerCompanyRSIvs 50-day avgvs 200-day avgvs 52-week high
MRNAModerna62+40.7%+181.7%−7.8%
MCKMcKesson76+12.1%+17.7%+0.0%
ISRGIntuitive Surgical65+8.9%−2.9%−28.0%
AAgilent62+8.9%+28.6%−1.5%
ABBVAbbVie71+8.8%+22.0%+0.0%
CAHCardinal Health74+8.4%+15.6%+0.0%
CICigna73+8.4%+7.8%−2.2%
TMOThermo Fisher64+8.4%+26.1%−0.9%
HCAHCA Healthcare63+7.6%+3.1%−15.8%
ZTSZoetis69+7.3%−17.2%−46.2%
What would change this

If the overbought readings cool while prices hold, the move is resting. If the count above the 50-day average (37 of 54 now) drops toward half, the selling would have spread across the sector rather than hitting a few stretched names.

Company deep dives

Eli Lilly, CVS Health, Bristol Myers Squibb and Abbott: the largest company, the week's best large one, the one the screens point down on and the first trending name to report.

Four companies, each picked by a rule rather than by taste: Eli Lilly — the largest health-care company by market value; CVS Health — the best week among those worth $100B or more; Bristol Myers Squibb — the largest company the trend screens point down on this week; Abbott — the first of the names the screens point up on to report results.

The four deep dives, share price indexed to 100 on Dec 31, 2025 (to Oct 16)
Eli LillyCVS HealthBristol Myers SquibbAbbott
Index (Dec 31 = 100)139.3665.9
2025-12-312026-10-16
The four deep dives side by side, as of the Oct 16 close (US-listed shares, USD)
MeasureEli Lilly (LLY)CVS Health (CVS)Bristol Myers Squibb (BMY)Abbott (ABT)
Close, Oct 16$1,257.03$92.36$59.75$104.89
Market value$1.18T$118B$124B$181B
1 week+6.6%+7.2%+1.1%+5.3%
Year to date+17.0%+16.4%+10.8%−16.3%
vs 50-day average+6.5%+0.7%−5.9%−0.9%
vs 200-day average+16.4%+4.7%+0.2%+2.0%
vs 52-week high−1.8%−16.5%−12.2%−19.7%
RSI69584459
Forward P/E26.610.89.017.3
PEG (1-year)0.771.77n/a1.75
Next reportOct 29Nov 4Oct 29Oct 21
Move options expect±5.7%±5.7%±3.9%±4.8%
Level to watch below$1,224.83$88.18none foundnone found

Forward P/E: share price ÷ analysts' expected earnings per share for the next financial year. PEG (1-year): forward P/E ÷ expected earnings growth over the next year only — n/a where growth is expected to be zero or negative, or for companies worth under $100B. Level to watch below: the closest price at least 2% under Friday's close where the stock turned at least twice in the past year (intraday trading), else its 50- or 200-day average — not a forecast that it will turn there.

Eli Lilly (LLY). Drugmaker; its obesity and diabetes medicines (tirzepatide, sold as Mounjaro and Zepbound) drive most of its growth. It gained 6.6% this week and is +17.0% this year, 1.8% below its highest close of the past year; it trades 6.5% above its 50-day average with an RSI of 69. It trades at 26.6 times next year's expected earnings (PEG ratio 0.77). It reports on Oct 29 before the open; options price a ±5.7% move against an average of ±8.0% after its past 8 reports.

What would change this — Eli Lilly

A close below $1,224.83, the nearest price where the stock turned at least twice before (2.6% under Friday's close), would mean this week’s gain is unwinding rather than consolidating.

CVS Health (CVS). Pharmacy chain that also owns the health insurer Aetna and a pharmacy-benefit manager. It gained 7.2% this week and is +16.4% this year, 16.5% below its highest close of the past year; it trades 0.7% above its 50-day average with an RSI of 58. It trades at 10.8 times next year's expected earnings (PEG ratio 1.77). It reports on Nov 4 before the open; options price a ±5.7% move against an average of ±5.7% after its past 8 reports.

What would change this — CVS Health

A close below $88.18, its 200-day average (4.5% under Friday's close), would mean this week’s gain is unwinding rather than consolidating.

Bristol Myers Squibb (BMY). Drugmaker: cancer, blood-thinner and immunology medicines. It gained 1.1% this week and is +10.8% this year, 12.2% below its highest close of the past year; it trades 5.9% below its 50-day average with an RSI of 44. It trades at 9.0 times next year's expected earnings. It reports on Oct 29 before the open; options price a ±3.9% move against an average of ±4.3% after its past 8 reports.

What would change this — Bristol Myers Squibb

Its Oct 29 report: a close outside the ±3.9% range options price — below $57.41 or above $62.09, measured from Friday's close — on Oct 29 or Oct 30 would mean the results moved the stock more than traders were ready for.

Abbott (ABT). Medical devices, diagnostic tests, nutrition and generic drugs; its glucose monitors are a fast-growing line. It gained 5.3% this week and is −16.3% this year, 19.7% below its highest close of the past year; it trades 0.9% below its 50-day average with an RSI of 59. It trades at 17.3 times next year's expected earnings (PEG ratio 1.75). It reports on Oct 21 before the open; options price a ±4.8% move against an average of ±5.9% after its past 7 reports.

What would change this — Abbott

Its Oct 21 report: a close outside the ±4.8% range options price — below $99.86 or above $109.92, measured from Friday's close — on Oct 21 or Oct 22 would mean the results moved the stock more than traders were ready for.

Scenarios

Three ways the coming weeks could go for health-care stocks, each tied to a level in this week's data — conditions to watch, not forecasts.

The rotation keeps going

If
technology keeps falling and XLV holds above its 20-day average ($170.89)
Then
health care extends its lead, and the insurers and drugmakers that led this week stay in front
Watch
the coming week's reports (Intuitive Surgical, Thermo Fisher, Abbott, Danaher and Elevance Health) clearing the moves options price

Leadership pauses

If
XLV trades between its 50-day average ($170.00) and this week's highs
Then
the overbought readings (RSI 66 on the sector fund) cool off without a fall in price
Watch
how many names the trend screens still point up on next Friday

The trade unwinds

If
XLV closes below its 50-day average ($170.00), or the S&P 500 fund wins back last Friday's $778.57 as technology rebounds
Then
money flows back to growth stocks and this week's health-care gains fade
Watch
Bristol Myers Squibb and the other names the screens already point down on